Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
8 May 2024
|
|
04:13 | Zuranolone 2 changes history +5,755 [Alen Antony (2×)] | |||
|
|
04:13 (cur | prev) +2,528 Alen Antony talk contribs | ||||
|
|
03:48 (cur | prev) +3,227 Alen Antony talk contribs | ||||
| 01:58 | User:Edzelco diffhist +22 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| 01:55 | Toripalimab-tpzi diffhist +45,965 Edzelco talk contribs | ||||
| 01:53 | Upload log Edzelco talk contribs uploaded File:LOQTORZI Dosage.png | ||||
7 May 2024
|
|
N 20:18 | Zuranolone 2 changes history +1,853 [Alen Antony (2×)] | |||
|
|
20:18 (cur | prev) +1,017 Alen Antony talk contribs | ||||
| N |
|
17:27 (cur | prev) +836 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...") | |||
|
|
04:14 | User:Archana.vajjala 5 changes history +4 [Archana.vajjala (5×)] | |||
|
|
04:14 (cur | prev) −25 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
04:09 (cur | prev) −40 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
03:59 (cur | prev) +26 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
03:56 (cur | prev) +3 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
03:56 (cur | prev) +40 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
| 03:37 | Perfluorhexyloctane diffhist +904 Alen Antony talk contribs | ||||
6 May 2024
| m 08:50 | Non-degenerate nucleotides per response element diffhist +144 Marshallsumter talk contribs (→Tabulation of counts) | ||||
3 May 2024
| N 22:57 | Xacduro- sulbactam and durlobactam diffhist +11,950 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin...") | ||||
|
|
N 19:10 | Perfluorhexyloctane 3 changes history +1,917 [Alen Antony (3×)] | |||
|
|
19:10 (cur | prev) +1,456 Alen Antony talk contribs | ||||
|
|
18:57 (cur | prev) +210 Alen Antony talk contribs | ||||
| N |
|
18:20 (cur | prev) +251 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}") | |||
2 May 2024
| N 15:29 | Trofinetide diffhist +74 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}") | ||||
|
|
N 04:04 | Zavegepant 2 changes history +4,397 [Alen Antony (2×)] | |||
|
|
04:04 (cur | prev) +2,901 Alen Antony talk contribs | ||||
| N |
|
03:29 (cur | prev) +1,496 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic...") | |||
|
|
02:13 | Omaveloxolone 4 changes history +3,035 [Alen Antony (4×)] | |||
|
|
02:13 (cur | prev) +439 Alen Antony talk contribs | ||||
|
|
02:10 (cur | prev) +619 Alen Antony talk contribs | ||||
|
|
02:05 (cur | prev) +435 Alen Antony talk contribs | ||||
|
|
01:14 (cur | prev) +1,542 Alen Antony talk contribs | ||||
1 May 2024
|
|
N 23:49 | Omaveloxolone 5 changes history +2,793 [Alen Antony (5×)] | |||
|
|
23:49 (cur | prev) +272 Alen Antony talk contribs | ||||
|
|
23:12 (cur | prev) +836 Alen Antony talk contribs | ||||
|
|
23:02 (cur | prev) +1,322 Alen Antony talk contribs | ||||
|
|
22:20 (cur | prev) +287 Alen Antony talk contribs | ||||
| N |
|
21:51 (cur | prev) +76 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=omaveloxolone }}") | |||
| 18:20 | Electronic medical record diffhist +1,643 Badgettrg talk contribs (→Documentation burden) | ||||
| N 15:46 | Nirsevimab diffhist +15,269 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=Nirsevimab |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season |hasBlackBo...") | ||||
|
|
15:31 | (Upload log) [Kosar Doraghi (2×)] | |||
|
|
15:31 Kosar Doraghi talk contribs uploaded File:IMG 1185.jpeg | ||||
|
|
15:29 Kosar Doraghi talk contribs uploaded File:IMG 1187.jpeg | ||||
| 14:19 | User creation log User account Rithish Nimmagadda talk contribs was created by Alberto Castro Molina talk contribs | ||||